Table 1.
Antibiotic exposures and CMV reactivation
| Yes, n | No, n | HR (95% CI) | P | |
|---|---|---|---|---|
| Model using antibiotic exposures by day +14 | ||||
| Fluoroquinolones (yes vs no) | 193 | 20 | 1.53 (0.69-3.43) | .30 |
| Third-generation or higher cephalosporins (yes vs no) | 142 | 71 | 0.72 (0.39-1.32) | .28 |
| Vancomycin (yes vs no) | 120 | 93 | 1.97 (1.11-3.51) | .02 |
| Piperacillin-tazobactam (yes vs no) | 44 | 169 | 0.90 (0.51-1.58) | .71 |
| Carbapenems (yes vs no) | 47 | 166 | 1.33 (0.78-2.26) | .29 |
| Metronidazole (yes vs no) | 35 | 178 | 0.92 (0.51-1.68) | .79 |
| Clindamycin (yes vs no) | 28 | 185 | 0.53 (0.24-1.19) | .12 |
| ATG during conditioning (yes vs no) | 36 | 177 | 0.62 (0.32-1.20) | .16 |
| Grade 2-4 acute GVHD (time varying) | 100 | 113 | 1.69 (1.05-2.73) | .03 |
| Ganciclovir/valganciclovir (time varying) | 40 | 173 | 0.45 (0.22-0.93) | .03 |
| Donor: UCB vs MSD | 146 | 67 | 0.19 (0.04-0.97) | .05 |
| UCB × time (d) interaction | 1.05 (1.01-1.09) | .01 | ||
| Model using antibiotic exposures by day +100 | ||||
| Fluoroquinolones (time varying) | 200 | 13 | 1.56 (0.62-3.93) | .34 |
| Third-generation or higher cephalosporins (time varying) | 172 | 41 | 1.21 (0.62-2.39) | .58 |
| Vancomycin (time varying) | 161 | 52 | 1.87 (0.99-3.54) | .05 |
| Piperacillin-tazobactam (time varying) | 65 | 148 | 0.78 (0.46-1.31) | .34 |
| Carbapenems (time varying) | 80 | 133 | 1.33 (0.82-2.14) | .25 |
| Metronidazole (time varying) | 57 | 156 | 0.64 (0.37-1.10) | .11 |
| Clindamycin (time varying) | 32 | 181 | 0.56 (0.26-1.18) | .13 |
| ATG during conditioning (yes vs no) | 36 | 177 | 0.62 (0.32-1.19) | .15 |
| Grade 2-4 acute GVHD (time varying) | 100 | 113 | 1.69 (1.04-2.73) | .03 |
| Ganciclovir/valganciclovir (time varying) | 40 | 173 | 0.43 (0.21-0.89) | .02 |
| Donor: UCB vs MSD | 146 | 67 | 0.18 (0.04-0.90) | .04 |
| UCB × time (d) interaction | 1.05 (1.02-1.09) | .01 |
The number of patients in each category is shown; for antibiotics, this is the number of patients exposed by day +14 or day +100, respectively. However, for time-varying variables, exposed patients were not “at risk” for the entire follow-up period.